Pfizer Inc. will present data from more than 50 abstracts at IDWeek 2026 in Washington, D.C. The presentations include 12 oral sessions covering the company’s infectious disease portfolio and pipeline, with developments in pneumococcal disease, respiratory syncytial virus (RSV), Lyme disease, and COVID-19.
Highlights include late-breaking Phase 2 data for Pfizer’s 25-valent pneumococcal conjugate vaccine candidate and Phase 3 results for its Lyme disease vaccine candidate, developed with Valneva.
The company will also present real-world data on the effectiveness of its RSV vaccine, ABRYSVO.